MIO Blood Glucose Monitoring System— 510(k) K223722

Substantially Equivalent

Mio Labs, Inc.

FDA 510(k) clearance K223722 for MIO Blood Glucose Monitoring System, Substantially Equivalent on 2023-06-28. Applicant: Mio Labs, Inc..

Clearance details

Applicant: Mio Labs, Inc.
Product code: Code NBW
Advisory panel: Clinical Chemistry
Date received: 2022-12-12
Decision date: 2023-06-28
Decision: Substantially Equivalent
Clearance type: Traditional
Location: Santa Clara, CA, US

Download summary PDF View on FDA.gov ↗

Adverse events under product code NBW

product code NBW

Death: 18
Injury: 4,740
Malfunction: 42,679
Other: 6
Total: 47,443

Source: openFDA MAUDE database, 2020-01-01 through 2026-04-23. Counts aggregate all devices under this product code, not just this specific clearance. Reports are submissions to FDA, not validated events. Search MAUDE directly →

Data sourced from openFDA. This site is unofficial and independent of the FDA.